Posted by: themossreports | December 16, 2010

FDA Rules Against Avastin


Today, December 16, the US Food and Drug Administration (FDA) took steps to disallow the use of Avastin (bevacizumab) in breast cancer. This overturns the previous director’s approval of the drug two years ago–a decision that was medically unwarranted but was worth hundreds of millions of dollars to Roche.

Dr. Richard Pazdur, the FDA’s chief of cancer drug review, said, “Given the number of serious and life-threatening side effects, the FDA does not believe there is a favorable risk-to-benefit ratio.”

I applaud this decision, as the data behind the use of Avastin in breast cancer was always very shaky. The company, however, is expected to appeal the ruling.

Advertisements

Responses

  1. Sure seems to be effective for Ovarian Cancer.

    • Its failure in one kind of cancer does not necessarily imply that it is not effective for other types.

    • Janet: Is your comment from personal experience? My husband’s oncologist is recommending Avastin for my husband right now (4th round stage 4 kidney cancer, a rare aggressive subtype) along with chemo. He is young and active and side effects have me concerned. He had carboplatin & taxol with success (an ovarian regimin).

  2. Excellent, everyone is seeing how few clothes the Emperor has!

  3. In a sense, I am pleased to see the FDA change its published decision. This can serve as an example of FDA independence from Big Pharma. I wish there were more such examples in what I see as a very troubled agency.

  4. I also applaud this decision. As a breast cancer survivor I find this toxic chemo drug not worth the side effects. I have seen several breast cancer patients take this with no visible health benefits.

  5. The problem from the beginning is that Avastin was NEVER a “breast cancer drug”.
    Nor is a colon cancer drug, lung cancer drug, etc. It’s target is VEGF (vascular endothelial growth factor). This target can be found in some breast cancers, some colon cancers, some lung cancers, etc. Until we begin doing meaningful research with molecular analyses of tissue sample looking for this and other targets on ALL cancer patients, we’re wasting our research dollars and people’s lives because the few breast cancer patients who express VEGF and may be helped by Avastin, will be washed out statistically by the majority who don’t express VEGF and therefore won’t respond.

  6. Dr. Linchitz raises a good point but the use of Avastin like all other toxic attempts to kill cancer cells, fails to address the environment that allowed the tumour to grow namely the patient surrounding it. Breast cancer patients with inactive NK (Natural Killer) lymphocytes have an increased recurrence and earlier mortality rate compared to those with active NK cells. What is not generally known is that mercury in the blood from dental amalgam has been proven to kill lymphocyes (hence very inactive) as well as depleting glutathione the major intracellular antioxidant. This evidence supports the late Dr. Issels, the renowned German oncologist’s contention that 98% of the over 12,000 patients he treated had significant causal factors in teeth, jaw and tonsils. Doctors’ examinations need to also include their patient’s teeth.

    • How can a person determine whether their NK lymphocytes are active or inactive? What kind of test reveals this?


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Categories

%d bloggers like this: